bio 300
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00504335)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Estrogen receptor betaAGONIST
ESR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bio 300
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02567799 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Henry Ford Health System, Humanetics Corporation, National Cancer Institute (NCI) |
| NCT00504335 | Phase 1 | Jun 1, 2007 | Department of Defense, Humanetics Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Humanetics Corporation | For profit | 2 | 2 | 2 | 2007 |
| Department of Defense | Government | 1 | 0 | 1 | 2007 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1